Carcinoma, Endometrioid - 25 Studies Found Active, not recruiting : Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer : Fallopian Tube Carcinosarcoma Fallopian Tube Clear Cell Adenocarcinoma Biological: Bevacizumab Given Recruiting : Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer : Clear Cell Adenocarcinoma Fallopian Tube Clear Cell Adenocarcinoma Biological: Bevacizumab Given Recruiting : Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer : Deleterious BRCA1 Gene Mutation Deleterious BRCA2 Gene Mutation Drug: Cediranib Maleate Given Recruiting : Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer : Deleterious BRCA1 Gene Mutation Deleterious BRCA2 Gene Mutation Drug: Cediranib Maleate Given Recruiting : Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer : Endometrial Adenocarcinoma Endometrial Adenosquamous Carcinoma Radiation: 3-Dimensional Conformal Radiation Therapy <<< Previous